Skip to main content

For urgent surgical problems, please contact the nearest hospital emergency department.

Fibroadenoma

Typical recovery: No recovery period is required for clinical assessment or ultrasound. After core-needle biopsy, most patients resume normal routine activity the same day or the following day, with mild bruising or soreness for a few days. After surgical excision, light activity is usually possible within a few days, while discomfort and wound healing commonly improve over one to two weeks depending on the size and location of the lesion.

Key points

  • Fibroadenoma is a benign breast lesion and is particularly common in adolescents and younger adult women.
  • Clinical examination alone cannot reliably distinguish every fibroadenoma from other breast masses, so appropriate imaging is important.
  • The investigation of a breast lump should be age-appropriate rather than using the same imaging pathway for every patient.
  • Ultrasound is especially useful in younger women and for characterising a palpable solid breast mass.
  • Not every lesion that looks like a fibroadenoma on ultrasound needs immediate biopsy. Management depends on the imaging category, age and clinical context.
  • When tissue diagnosis is required for a solid fibroepithelial lesion, image-guided core-needle biopsy is generally preferred over FNAC because tissue architecture helps distinguish fibroadenoma from other lesions.
  • A pathology report should always be interpreted together with the imaging findings. Radiology-pathology discordance requires further assessment.
  • A core-biopsy–proven, imaging-concordant fibroadenoma without atypia generally does not require surgical excision.
  • According to current ASBrS/SBI guidance, a concordant core-biopsy–proven fibroadenoma without atypia does not require dedicated imaging surveillance and can return to age-appropriate breast screening.
  • This is different from an imaging-only BI-RADS 3 mass that has not been biopsied; such a lesion may be followed with interval imaging according to the radiologist's recommendation.
  • Excision may be appropriate for significant symptoms, substantive growth, sufficiently large size, cosmetic problems or patient preference.
  • A rapidly enlarging or atypical fibroepithelial lesion should be reassessed because phyllodes tumour can sometimes resemble fibroadenoma clinically, radiologically or on limited biopsy material.
  • A pathology diagnosis of fibroepithelial lesion with concern for phyllodes tumour is managed differently from a straightforward concordant fibroadenoma and commonly requires excisional biopsy.
  • Fibroadenomas may enlarge during pregnancy or other hormonal changes and this alone does not automatically indicate malignancy.
  • Routine removal of every fibroadenoma exposes patients to unnecessary scars, possible contour change and surgical morbidity without clinical benefit.

Overview

A fibroadenoma is a benign fibroepithelial breast lesion composed of both glandular and stromal tissue. It is one of the most common causes of a solid breast lump in adolescents and younger adult women, although it can occur at other ages. A typical fibroadenoma is usually well-defined, mobile, firm or rubbery and painless, but examination alone cannot reliably establish the diagnosis. Assessment therefore depends on the patient's age, clinical findings and appropriate breast imaging. Ultrasound is particularly useful in younger women, while diagnostic mammography or tomosynthesis may also be appropriate according to age and clinical context. If imaging is clearly benign or probably benign, immediate biopsy may not always be required. When tissue diagnosis is needed, image-guided core-needle biopsy is generally preferred because it preserves tissue architecture and helps distinguish fibroadenoma from other fibroepithelial lesions. Management should be based on concordance between the clinical examination, imaging and pathology. A core-biopsy–proven fibroadenoma without atypia that is concordant with the imaging can usually be observed. Surgical excision is considered when the lesion causes significant symptoms, shows substantive growth, becomes sufficiently large or cosmetically troublesome, the patient prefers removal after informed discussion, or when imaging or pathology raises concern for a phyllodes tumour or another diagnosis. Fibroadenoma itself is benign and does not routinely require removal simply because it is present.

Signs & symptoms

  • A painless, well-defined breast lump discovered by the patient or during examination.
  • A firm or rubbery lump that may feel mobile within the breast.
  • A breast lump that has remained stable for months or years.
  • A fibroadenoma that becomes more noticeable or enlarges during periods of hormonal change, including pregnancy.
  • Local discomfort or tenderness in some patients, although many fibroadenomas are completely painless.
  • A large lesion causing visible asymmetry, distortion or cosmetic concern.
  • Rapid or sustained enlargement, which requires reassessment because an enlarging fibroepithelial lesion cannot always be assumed to remain a simple fibroadenoma.

How assessment and treatment are planned

  1. 1

    Take a focused history including duration of the lump, change in size, pain, menstrual or pregnancy-related changes, previous breast lesions and relevant family history.

  2. 2

    Perform a clinical breast examination and assess both breasts and the regional lymph-node areas.

  3. 3

    Select imaging according to age and clinical context. Breast ultrasound is particularly useful in younger women and for characterising a palpable solid lesion.

  4. 4

    Use diagnostic mammography or digital breast tomosynthesis when appropriate for the patient's age, examination findings and overall breast-imaging assessment.

  5. 5

    Assign an imaging assessment such as BI-RADS and determine whether observation, interval imaging or tissue sampling is appropriate.

  6. 6

    If tissue diagnosis is needed, perform an image-guided core-needle biopsy whenever appropriate. Core biopsy generally provides more useful architectural information than FNAC for a solid fibroepithelial breast lesion.

  7. 7

    Correlate the pathology with the imaging findings. A diagnosis of fibroadenoma should not be accepted uncritically when the clinical, imaging and pathological findings are discordant.

  8. 8

    Observe a core-biopsy–proven, concordant fibroadenoma without atypia when there are no significant symptoms or other indications for intervention.

  9. 9

    Reassess a lesion that shows substantive growth, develops atypical imaging features or no longer fits the expected clinical behaviour of a fibroadenoma.

  10. 10

    Discuss excision when the lesion is symptomatic, significantly enlarging, large or cosmetically troublesome, when the patient prefers removal after counselling, or when there is concern for phyllodes tumour or another diagnosis.

  11. 11

    When surgical excision is chosen, plan the incision with attention to breast contour, scar position, nipple sensation and cosmetic outcome, and remove the lesion completely without intentionally transecting the mass.

Preparation

  • Bring previous breast ultrasound, mammography or tomosynthesis reports and, where possible, the actual images for comparison.
  • Bring any previous FNAC, core-biopsy or surgical pathology reports relating to the same or another breast lump.
  • Tell the clinician how long the lump has been present and whether its size has changed.
  • Mention pregnancy, breastfeeding or recent major hormonal changes because fibroadenomas can respond to hormonal stimulation.
  • Give details of previous breast operations, biopsies or known benign breast disease.
  • Discuss relevant family history of breast or ovarian cancer and any known hereditary cancer predisposition.
  • Bring a current medication list, particularly anticoagulants or antiplatelet medicines if a core biopsy or operation may be planned.
  • Do not stop blood-thinning medication on your own; medication management around biopsy or surgery should be individualised.
  • If surgical removal is being considered, discuss whether the main reason is pain, growth, cosmetic concern, diagnostic uncertainty or personal preference so the expected benefit is clear.

Recovery and aftercare

  • If the lesion is being observed, follow the imaging plan stated in the radiology report rather than arranging repeated scans without a defined indication.
  • A core-biopsy–proven fibroadenoma that is concordant with imaging and contains no atypia generally does not require dedicated fibroadenoma surveillance and can return to age-appropriate screening.
  • Return for reassessment if a previously stable lump shows clear substantive growth or develops new symptoms.
  • After core biopsy, mild soreness, bruising and a small amount of local swelling are common for a short period.
  • Keep the biopsy site clean and follow the dressing instructions provided by the treating team.
  • Seek review if there is persistent bleeding, increasing redness, fever or progressively worsening pain after biopsy.
  • After surgical excision, follow wound-care and activity advice given by the surgeon and attend the postoperative pathology review.
  • The final excision pathology should be reviewed even when the preoperative diagnosis was fibroadenoma, particularly if the lesion was enlarging or there had been concern for a fibroepithelial or phyllodes lesion.
  • A scar or small change in breast contour can occur after excision, particularly after removal of a large lesion; incision planning therefore forms part of treatment decision-making.

Risks and possible complications

  • An imaging diagnosis of probable fibroadenoma can occasionally represent another lesion, which is why imaging category and follow-up recommendations matter.
  • A limited tissue sample can sometimes be reported as a fibroepithelial lesion without reliably distinguishing fibroadenoma from phyllodes tumour.
  • Failure to recognise radiology-pathology discordance can delay diagnosis of a different breast lesion.
  • A fibroadenoma may increase in size and become painful or cosmetically noticeable.
  • Repeated unnecessary imaging or biopsies can increase anxiety and intervention without improving outcomes in a proven concordant benign lesion.
  • Core biopsy can cause temporary pain, bruising, bleeding or haematoma; infection is uncommon.
  • Surgical excision leaves a scar and can occasionally produce contour change, altered sensation, bleeding, infection or seroma.
  • Removal of a large fibroadenoma can create a temporary or persistent volume defect in the breast.
  • Recurrence at the same site after complete excision is uncommon, but additional fibroadenomas can develop elsewhere in either breast.
  • A rapidly enlarging lesion believed to be a fibroadenoma may occasionally prove to be a phyllodes tumour or another diagnosis, which is why change in behaviour warrants reassessment.

When to arrange prompt medical assessment

  • A newly discovered breast lump that has not previously been assessed.
  • A previously diagnosed fibroadenoma that is clearly increasing in size.
  • Rapid enlargement over a relatively short period, particularly if the lesion becomes large or distorts the breast.
  • Development of persistent focal pain or significant tenderness in or around a known breast lump.
  • New skin tethering, dimpling, nipple retraction or another change that is not typical of a stable fibroadenoma.
  • Bloody or otherwise concerning nipple discharge associated with a breast lump.
  • A new persistent lump in the axilla or another regional lymph-node area.
  • A breast mass that behaves differently from previous imaging or pathology expectations, even if it was previously labelled benign.

When to go to an emergency department now

  • Rapidly increasing swelling or significant bleeding after a breast biopsy or operation that does not settle with firm direct pressure.
  • Severe breast swelling accompanied by high fever, systemic illness or rapidly spreading redness, which is not typical of fibroadenoma and requires urgent assessment for another diagnosis.

Myth vs fact

Frequently asked questions

Sources

Medically reviewed by Dr. Shams Alam Mohammed Tahir, MBBS, MS (General Surgery). Last reviewed 2026-09-18.

WhatsApp